<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531815</url>
  </required_header>
  <id_info>
    <org_study_id>B7841001</org_study_id>
    <secondary_id>2015-001821-17</secondary_id>
    <nct_id>NCT02531815</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of PF-06741086 In Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Intravenous Or Subcutaneous Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06741086 In Healthy Subjects And An Open-label Evaluation In Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind,
      placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of PF-06741086.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with laboratory abnormalities</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in vital signs</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
    <description>blood pressure, pulse rate, temperature, respiration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 1 to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with changes from baseline in physical examination</measure>
    <time_frame>Day 1 to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with infusion site reactions</measure>
    <time_frame>Day 1 up to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with injection site reactions</measure>
    <time_frame>Day 1 to Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PF-06741086 concentrations</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for Cmax (Tmax)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to last quantifiable concentration (AUClast)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t 1/2)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
    <description>Intravenous administration only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
    <description>Subcutaneous administration only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
    <description>Intravenous administration only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
    <description>Subcutaneous administration only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability (F) [F = AUC (inf,sc) / AUC (inf,iv)]</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total tissue factor pathway inhibitor concentrations over time</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
    <description>may include lag time, peak thrombin generation, and endogenous thrombin generation potential</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin fragment 1+2 (PF1+2) concentrations over time</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer concentrations over time</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dilute prothrombin time (dPT)</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti-drug antibody (ADA) and neutralizing antibody (NAb) production</measure>
    <time_frame>Day 1 up to Day 84</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (SC) PF-06741086, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (SC) PF-06741086, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (Intravenous [IV]) PF-06741086, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 (IV) PF-06741086, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 (IV) PF-06741086, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 (IV) PF-06741086, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 (subcutaneous [SC]) PF-06741086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)</description>
    <arm_group_label>Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 2 (SC) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 3 (SC) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 4 (Intravenous [IV]) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 5 (IV) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 6 (IV) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 7 (IV) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 8 (subcutaneous [SC]) PF-06741086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for PF-06741086, single dose</description>
    <arm_group_label>Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 2 (SC) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 3 (SC) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 4 (Intravenous [IV]) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 5 (IV) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 6 (IV) PF-06741086, Placebo</arm_group_label>
    <arm_group_label>Cohort 7 (IV) PF-06741086, Placebo</arm_group_label>
    <other_name>saline placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)
             and 100 kg (220 lbs).

        Exclusion Criteria:

          -  Increased risk of thrombosis (coronary artery disease, hypercholesterolemia, diabetes)

          -  Use of nicotine/tobacco products

          -  Clotting disorders
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7841001&amp;StudyName=A%20Randomized%2C%20Double-blind%2C%20Sponsor-open%2C%20Placebo-controlled%2C%20Single%20Intravenous%20Or%20Subcutaneous%20Dose%20Escalation%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%2C%20And%20Pharmacodynamics%20Of%20Pf-06741086%20In%20Healthy%20Subjects%20And%20An%20Open-label%20Evaluation%20In%20Healthy%20Japanese%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>Phase 1</keyword>
  <keyword>first in human</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>tissue factor pathway inhibitor</keyword>
  <keyword>japanese</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

